Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 9/20 | 0.63 |
| ▸ | NAMPT | P43490 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | ME3 | Q16798 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072388 | 0.83 | TRPV1 (0.64) | CHRM5HSD17B10ME3KDM4E | |
| SCHEMBL5799490 | 0.78 | CHRM5 (0.49) | CHRM5HSD17B10ME3 | |
| SCHEMBL6072188 | 0.77 | CHRM5 (0.45) | CHRM5 | |
| SCHEMBL26347535 | 0.77 | CHRM5 (1.00) | CHRM5 | |
| SCHEMBL5798538 | 0.77 | PDE3B (0.46) | CHRM5HSD17B10KDM4E | |
| SCHEMBL6072444 | 0.77 | CHRM5 (0.45) | CHRM5HSD17B10GSK3BME3 | |
| SCHEMBL6072197 | 0.77 | CHRM5 (0.45) | CHRM5HSD17B10ME3 | |
| SCHEMBL30410549 | 0.75 | CHRM5 (0.91) | CHRM5 | |
| SCHEMBL26347578 | 0.75 | CHRM5 (0.91) | CHRM5 | |
| SCHEMBL26347579 | 0.75 | CHRM5 (0.91) | CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | CHRM5 1551/4885NAMPT 1163/4885PKM 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.